Angiotensin Receptor Blockers : Current Status and Future ProspectsRAM, C. Venkata S.The American journal of medicine. 2008, Vol 121, Num 8, pp 656-663, issn 0002-9343, 8 p.Article

Angiotensin II-receptor blocker dosages : How high should we go?DÜSING, R.International journal of clinical practice (Esher). 2006, Vol 60, Num 2, pp 179-183, issn 1368-5031, 5 p.Article

Increased Capillary Branching Contributes to Angiotensin Type 1 Receptor Blocker (ARB)―Induced Regression of SclerosisSCRUGGS, Benjamin S; YIQIN ZUO; DONNERT, Ellen et al.The American journal of pathology. 2011, Vol 178, Num 4, pp 1891-1898, issn 0002-9440, 8 p.Article

Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancerVOLPE, Massimo; AZIZI, Michel; JAN DANSER, A. H et al.European heart journal. 2011, Vol 32, Num 1, pp 19-22, issn 0195-668X, 4 p.Article

Angiotensin II can induce and potentiate shape change in human platelets : effect of losartanJAGROOP, I. A; MIKHAILIDIS, D. P.Journal of human hypertension. 2000, Vol 14, Num 9, pp 581-585, issn 0950-9240Article

High-Affinity Interaction of Sartans with H⁺/Peptide TransportersKNÜTTER, Ilka; KOTTRA, Gabor; FISCHER, Wiebke et al.Drug metabolism and disposition. 2009, Vol 37, Num 1, pp 143-149, issn 0090-9556, 7 p.Article

2nd international forum on angiotensin II receptor antagonism (Monte-Carlo, January 24-26 2001, abstracts)International forum on angiotensin II receptor antagonism. 2001, 44 p.Conference Proceedings

Vaisseaux, cœur et rein: l'angiotensine II toujours d'actualité: Agir avant l'accident: impact des antagonistes de l'angiotensine IIBONNET, J; OBREJA, D.Archives des maladies du coeur et des vaisseaux. Pratique. 2011, Num MARS, issn 1261-694X, S1-S3, SUP1Article

Angiotensin II receptor blockers for the treatment of heart failure : A class effect?HUDSON, Marie; HUMPHRIES, Karin; TU, Jack V et al.Pharmacotherapy. 2007, Vol 27, Num 4, pp 526-534, issn 0277-0008, 9 p.Article

Effect of losorlan on muscle sympathetic activity and baroreceptor function in systemic hypertensionBECHIR, Markus; ENSELEIT, Frank; CHENEVARD, Rémy et al.The American journal of cardiology. 2005, Vol 95, Num 1, pp 129-131, issn 0002-9149, 3 p.Article

Angiotensin II receptor antagonists: Role in hypertension, cardiovascular disease, and renoprotectionAPPEL, Gerald B; APPEL, Alice S.Progress in cardiovascular diseases. 2004, Vol 47, Num 2, pp 105-115, issn 0033-0620, 11 p.Article

les antagonistes des récepteurs de l'angiotensine II: différents ou équivalents? = Angiotensin II receptor antagonists: are they all the same ?MOUNIER-VEHIER, C; DEVOS, P.La Presse médicale (1983). 2001, Vol 30, Num 21, pp 1072-1075, issn 0755-4982Article

New Clinical Trials of Angiotensin Blockade in Cardiovascular DiseaseJULIUS, Stevo.American journal of hypertension. 2000, Vol 13, Num 5, issn 0895-7061, 30 p., 2Serial Issue

Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedemaWARNER, K. K; VISCONTI, J. A; TSCHAMPEL, M. M et al.The Annals of pharmacotherapy. 2000, Vol 34, Num 4, pp 526-528, issn 1060-0280Article

Angiotensin II antagonistsSMITH, R. D; CUNNINGHAM, G; KIVLIGHN, S. D et al.Emerging drugs. 1998, Vol 3, pp 81-93, issn 1361-9195Article

Angiotensin Receptor Blockers and Angiotensin- Converting Enzyme Inhibitors: Challenges in Comparative Effectiveness Using Medicare DataSETOGUCHI, S; SHRANK, W. H; LIU, J et al.Clinical pharmacology and therapeutics. 2011, Vol 89, Num 5, pp 674-682, issn 0009-9236, 9 p.Article

Association IEC-sartans: que faut-il en penser ? : Hypertension arterielleLa Revue du praticien (Paris). 2010, Vol 60, Num 5, issn 0035-2640, p. 632Article

Sartans: excès de cancers ? = Angiotensin-receptor blocking agent (sartans) and risk of cancersLa Revue Prescrire. 2010, Vol 30, Num 323, issn 0247-7750, p. 672Article

Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors : Where do we stand now?BÖHM, Michael.The American journal of cardiology. 2007, Vol 100, Num 3, issn 0002-9149, 38J-44J, SUPAConference Paper

Prescription des antagonistes des récepteurs de l'angiotensine. II: (AT1-bloquants) = Angiotensin II receptor antagonisteGIRERD, X.Concours médical (Paris). 1999, Vol 121, Num 32, pp 2489-2491, issn 0010-5309Article

Pharmacokinetic- pharmacodynamic interactions of candesartan cilexetil and losartanAZIZI, M; CHATELLIER, G; GUYENE, T.-T et al.Journal of hypertension. 1999, Vol 17, Num 4, pp 561-568, issn 0263-6352Article

Solubilities of losartan polymorphsCROCKER, L. S; MCCAULEY, J. A.Pharmazie. 1997, Vol 52, Num 1, issn 0031-7144, p. 72Article

Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteersBELZ, G. G; FUCHS, B; MALERCZYK, C et al.Journal of human hypertension. 1997, Vol 11, pp S45-S47, issn 0950-9240, SUP2Article

Pharmacokinetic drug interaction studies with candesartan cilexetilJONKMAN, J. H. G; VAN LIER, J. J; VAN HEININGEN, P. N. M et al.Journal of human hypertension. 1997, Vol 11, pp S31-S35, issn 0950-9240, SUP2Article

Angiotensin II antagonism refined: candesartan cilexetil. A novel long-acting selective AT¹ receptor blockerSEVER, P; MENARD, J.Journal of human hypertension. 1997, Vol 11, issn 0950-9240, 97 p., SUP2Serial Issue